Products
Samatatug Biosimilar Monoclonal Antibody (Tissue Factor) for Research
Cat No.: GMP-Bios-INN-1382
Anti-F3/CD142 therapeutic antibody (Pre-made Samatatug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Samatatug (development code XB002) is a monoclonal antibody targeting tissue factor (F3). It is developed by Iconic Therapeutics and Exelixis for Solid tumours in Phase I development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1382-1mg | 1mg | 3090 |
| GMP-Bios-INN-1382-10mg | 10mg | |
| GMP-Bios-INN-1382-100mg | 100mg | |
| GMP-Bios-INN-1382-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Samatatug biosimilar, Whole mAb, Anti-F3/CD142 Antibody: Anti-F3/Tissue Factor/Coagulation Factor III/CD142 therapeutic antibody |
| INN Name | Samatatug |
| Target | F3/CD142 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Iconic Therapeutics;Exelixis |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Solid tumours |
| Production | na |
| Development Tech | na |
